Aptar makes digital health play, agreeing deal to buy VoluntisDrug delivery specialist Aptar Group has agreed a deal to take a near two-thirds share in Voluntis, a Share XAptar makes digital health play, agreeing deal to buy Voluntishttps://pharmaphorum.com/news/aptar-makes-digital-health-play-agreeing-deal-to-buy-voluntis/
BioNTech grows in cell therapies, buying Kite’s TCR platformBioNTech has found a use for some of the windfall cash it has raked in from its COVID-19 Share XBioNTech grows in cell therapies, buying Kite’s TCR platformhttps://pharmaphorum.com/news/biontech-grows-in-cell-therapies-buying-kites-tcr-platform/
Lilly grabs glucose-sensing insulin tech, buying Protomer in $1bn dealEli Lilly bought a stake in Protomer Technologies and its glucose-sensing insulin platform last year, and it must Share XLilly grabs glucose-sensing insulin tech, buying Protomer in $1bn dealhttps://pharmaphorum.com/news/lilly-grabs-glucose-sensing-insulin-tech-buying-protomer-in-1bn-deal/
Final hurdle falls as UK backs AZ’s $39bn takeover of AlexionThe UK’s competition regulator has approved AstraZeneca’s $39 billion acquisition of US-based drugmaker Alexion, without opting for a Share XFinal hurdle falls as UK backs AZ’s $39bn takeover of Alexionhttps://pharmaphorum.com/news/final-hurdle-falls-as-uk-backs-azs-39bn-takeover-of-alexion/
Novo Nordisk bulks up in rare diseases with $1.2bn Prothena dealDiabetes giant Novo Nordisk has opened a new front in its rare disease R&D, thanks to an acquisition Share XNovo Nordisk bulks up in rare diseases with $1.2bn Prothena dealhttps://pharmaphorum.com/news/novo-nordisk-bulks-up-in-rare-diseases-with-1-2bn-prothena-deal/
Big tobacco’s PMI makes another pharma foray with Vectura dealTobacco giant Philip Morris International (PMI) has doubled down on its move into the pharmaceutical sector, following up Share XBig tobacco’s PMI makes another pharma foray with Vectura dealhttps://pharmaphorum.com/news/big-tobaccos-pmi-makes-another-pharma-foray-with-vectura-deal/
Another hurdle down as EU clears AstraZeneca’s Alexion takeoverThe European Commission has given competition clearance to the $39 billion acquisition of Alexion by AstraZeneca, leaving the Share XAnother hurdle down as EU clears AstraZeneca’s Alexion takeoverhttps://pharmaphorum.com/news/another-hurdle-down-as-eu-clears-astrazenecas-alexion-takeover/
AbbVie jumps on the BCMA train, opting into TeneoOne buyAfter dipping its toe into the BCMA water with an option to codevelop a bispecific antibody developed by Share XAbbVie jumps on the BCMA train, opting into TeneoOne buyhttps://pharmaphorum.com/news/abbvie-jumps-on-the-bcma-train-opting-into-teneoone-buy/
GSK sees £20bn peak sales potential in late-stage pipelineGlaxoSmithKline’s pitch to shareholders kicked off this afternoon with an optimistic view of its late-stage pipeline – including Share XGSK sees £20bn peak sales potential in late-stage pipelinehttps://pharmaphorum.com/news/gsk-sees-20bn-peak-sales-potential-in-late-stage-pipeline/
